Navigation Links
Full Agenda Announced for CMAC 2011 - CBI'S 2nd Annual Commercialization and Market Access Congress
Date:10/18/2011

WOBURN, Mass., Oct. 18, 2011 /PRNewswire/ -- CBI is pleased to announce the full agenda for CMAC 2011 - CBI's 2nd Annual Commercialization and Market Access Congress, being held December 6-7, 2011 in Philadelphia, PA. The program, sponsored by Campbell Alliance and McKesson Specialty Care Solutions, delivers pre- and post-launch strategies, dynamic programming and extensive coverage of market access trends.

Anchored by conference chairman, Robert Besthof, Vice President, Commercial Lead, ERP U.S. & Puerto Rico, Pfizer Inc., CMAC 2011 boasts an impressive speaker lineup from AstraZeneca, Baxter, Bristol-Myers Squibb, Daiichi Sankyo, Endo, Eli Lilly, ImClone, InterMune, Metamark Genetics, Grifols, ISTA Pharmaceuticals, Shire, Vertex and many more. Attendees have the opportunity to customize their congress by choosing between workshops, pre- and post-launch tracks and participating in interactive panel discussions. Session highlights include:

  • Product Commercialization Simulation from Candidate Selection through Launch
  • Reimbursement Strategies to Ensure Favorable Coverage, Coding and Payment Decisions
  • The Emergence of Personalized Medicine
  • Global Rollout
  • Brand Commercialization in a Crowded Therapeutic Marketplace
  • Building Specialty Launch Teams
  • Re-Positioning Products Post-Launch
  • KOL Engagement to Optimize Commercialization Efforts

CMAC 2011 is the industry's only opportunity to participate in an executive-level exchange addressing the overarching product development and launch environment, as well as tactical approaches for pricing, reimbursement, product launch, commercial strategy, branding, managed care and HEOR. For more information on the conference or to view the entire agenda, please visit http://www.cbinet.com/cmac2011.  

About CBI:

CBI, a subsidiary of Advanstar, is the leading provider of market-driven, unbiased conferences for the pharmaceutical, biotechnology, medical device and healthcare industries. CBI offers specialized information presented in interactive formats by thought leaders and regulators. For more information, please visit http://www.cbinet.com.

For additional information or media inquiries, please contact: Emily Forest, Marketing Manager, at 339-298-2156.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE CBI
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma
2. TechConnect World Publishes Conference Agenda Featuring More than 2,700 Presentations Addressing Nano, Bio and Clean Technologies
3. American Society of Anesthesiologists Primary Agenda Displayed Says Dr. Barry Friedberg of Cosmetic Surgery Anesthesia
4. CBI Announces the Agenda for Their West Coast Forum on Clinical Supply Chain Management
5. CBI Announces the Agenda for Their 6th Annual Pharmaceutical/Biotech Accounting and Reporting Congress
6. 'Biopolymers Symposium 2010' Agenda Announced
7. Full Agenda Announced for CBIs Commercialization and Market Access Congress (CMAC 2010)
8. 2008 National Ergonomics Conference Schedule Announced, Features Four New Tracks of Programming and Focus on Corporate Sustainability and Productivity; Most Product Debuts in Expos 14-Year History
9. 2008 R&D Innovator of the Year & Scientist of the Year Finalists Announced
10. First Annual Arizona Biotech Day Announced for October 23rd 2008
11. Presenters Announced For MichBio Expos Emerging Business Showcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... WA (PRWEB) , ... March 01, 2017 , ... ... research into the physiology of aging into clinical applications, announces the formation of ... proprietary oral-transmucosal dosage form of resveratrol, the drug which has been discussed in ...
(Date:2/28/2017)... Linda, Ca (PRWEB) , ... February 28, 2017 , ... ... molecular interactions. SPR is an optical phenomenon that is sensitive to changes in the ... resonance condition is affected by changes in refractive index occurring up to 300 nm ...
(Date:2/28/2017)... , Feb. 28, 2017  Phosphorus, a ... today the formation of the Phosphorus Scientific Advisory ... experts chosen to advise the company on the ... multi-site research initiatives. Please visit http://phosphorus.com/about-us/ ... initiatives. "We,ve gathered some of the ...
(Date:2/28/2017)... -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing ... diseases, asthma and allergic diseases and cancer, today ... full year ended December 31, 2016 and provided ... clinical highlights. "During 2016, we made ... starting five clinical trials across our XmAb portfolio.  ...
Breaking Biology Technology:
(Date:2/8/2017)... 7, 2017 The biometrics market has ... confluence of organizations, desires to better authenticate or ... (password and challenge questions), biometrics is quickly working ... The market is driven by use cases, though ... and enterprise uses cases, with consumer-facing use cases ...
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
Breaking Biology News(10 mins):